Contribution: Industrial Research Assistance Program – Contributions to Firms
Bold Therapeutics Inc.
$422,667.00
Preclinical investigation of BOLD-100 molecular mechanisms associated with susceptibility to treatment, and novel therapeutic combinations
FY 2020-21 · 2020-05-01
Summary
BOLD-100 is a novel therapeutic that synergies with existing drugs to treat cancer. Project investigates the underlying mechanism behind BOLD-100, leading to new treatment combinations in additional cancer indications.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
748003712
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-05-01 | 2020-21 | $208,667.00 |
| 1 | 2020-05-01 | 2020-21 | $312,667.00 |
| 2 | 2020-05-01 | 2020-21 | $422,667.00 |
| 3 | 2020-05-01 | 2020-21 | $422,667.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 91 jours.
Agreement End Date
2022-06-30
Agreement Number
948659
Agreement Start Date
2020-05-01
Agreement Title
Preclinical investigation of BOLD-100 molecular mechanisms associated with susceptibility to treatment, and novel therapeutic combinations
Agreement Title (French)
Étude préclinique des mécanismes moléculaires de BOLD-100 associés à la sensibilité au traitement, et nouvelles combinaisons thérapeutiques
Agreement Type
Contribution
Agreement Value
$422,667.00
Amendment Date
2022-03-09
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
BOLD-100 is a novel therapeutic that synergies with existing drugs to treat cancer. Project investigates the underlying mechanism behind BOLD-100, leading to new treatment combinations in additional cancer indications.
Description (French)
BOLD-100 est un nouveau médicament qui agit en synergie avec les médicaments existants pour traiter le cancer. Le projet permet d'étudier le mécanisme sous-jacent de BOLD-100, ce qui conduit à de nouvelles combinaisons de traitement dans des indications supplémentaires pour le cancer.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Centre
Federal Riding (French)
Vancouver-Centre
Federal Riding Number
59034
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
748003712
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Bold Therapeutics Inc.
Recipient Postal Code
V6C 1E1
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q1-948659
